Loading...
01/10 16:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a positive outlook with revenue and recurring revenue growth, improved gross margins, and reduced operating expenses. The Q&A section reinforced confidence in sales transformation and balance sheet improvements. Despite conservative guidance, the company is on track for a strong 2025 with reduced cash usage and a focus on market expansion. The shareholder return plan is also a positive aspect. However, regulatory and supply chain risks are noted, but the overall sentiment is positive, predicting a 2% to 8% stock price increase.
Revenue $29.8 million, grew 6% from the first quarter of 2024 due to higher recurring revenue across a larger installed base.
Product Revenue $21.3 million, grew 4% from $20.4 million in the prior year, with console revenue of $7.1 million and consumable revenue of $14.2 million.
Console Revenue $7.1 million, grew 23% sequentially.
Service and Other Revenue $8.5 million, grew 9% from $7.7 million in the prior year period.
Recurring Revenue $22.7 million, increased 20% over the first quarter of 2024.
Gross Margin 37.6%, increased 650 basis points from 31.1% in the prior year period.
Product Gross Margin 48.4%, increased 860 basis points year-over-year.
Service and Other Gross Margin 10.3%, increased 230 basis points from 8% in the prior year period.
Operating Expenses $24.6 million, declined by 30% from the prior year period.
Non-GAAP Operating Loss $13.4 million, 49% below the operating loss in the prior year period.
Net Loss $22.8 million or $3.24 per share, 22% lower than the first quarter of 2024.
Cash Position $192.3 million in cash, cash equivalents, short-term investments and restricted cash.
Cash Use Projection Expect to use under $50 million in cash in 2025, which is less than half the $103 million used in 2024.
Console Revenue Growth: Console revenue grew 23% sequentially, indicating strong demand and utilization.
Recurring Revenue Growth: Recurring revenue reached $22.7 million, a 20% increase year-over-year, driven by strong utilization of Tablo.
Cumulative Treatments: Outset shipped its 3 millionth treatment, achieving this milestone in just over 12 months.
Market Expansion in Acute Care: Outset continues to penetrate acute care providers, with a large regional IDN deploying their 100th Tablo.
Home Market Expansion: Expanded Tablo's use among midsized dialysis providers and contracted with a previously unadopted MDO.
Gross Margin Improvement: Non-GAAP gross margin increased to 37.6%, with product gross margin nearing 50%.
Cost Reduction: Actions taken to remove approximately $80 million of annualized spend contributed to the lowest non-GAAP operating loss since IPO.
Path to Profitability: Outset is focused on top-line growth, gross margin expansion, and disciplined spend management to reach cash flow breakeven.
Employee Stock Plan: Proxy statement filed to approve a one-time increase in stock pool for employee grants to attract and retain talent.
Regulatory Issues: Federal funding cuts have made the healthcare environment more dynamic, impacting financial planning for 2025.
Supply Chain Challenges: The company is experiencing lower absorption of manufacturing overhead due to a reduced console build plan and efforts to reduce inventory levels.
Economic Factors: The healthcare market is affected by federal funding cuts, which may influence capital expenditures and operational decisions of healthcare providers.
Competitive Pressures: The company faces competition in the healthcare market, necessitating a strong focus on maintaining and expanding its market share.
Operational Risks: The company is working towards profitability while managing operational expenses, which could be impacted by market dynamics and execution challenges.
Console Revenue Growth: Console revenue grew 23% sequentially, indicating a strong focus on reigniting console growth.
Recurring Revenue Growth: Recurring revenue of $22.7 million grew 20% over the first quarter of last year, reflecting strong utilization of Tablo.
Operational Efficiency: Actions taken to remove approximately $80 million of annualized spend delivered leverage, resulting in the lowest non-GAAP operating loss since the IPO.
Market Expansion: Continued penetration within acute care providers and expansion into subacute facilities, indicating a strategic initiative to broaden market reach.
Customer Adoption: New customers adopting Tablo and existing customers expanding usage, showcasing effective sales transformation and market recognition.
Tariff Exemptions: Confirmation of tariff exemptions for Tablo products, ensuring no impact from proposed or implemented tariffs.
2025 Revenue Guidance: Expected revenue for the full year to be between $115 million to $125 million, implying a 10% growth in installed base and recurring revenue.
Gross Margin Expectations: Gross margin expected to be in the high 30% range for the full year, with an exit above 40% in Q4 2025.
Operating Expenses: Anticipated operating expenses of roughly $90 million for 2025.
Cash Utilization: Expected to use under $50 million in cash in 2025, significantly less than the $103 million used in 2024.
Path to Profitability: Plan to reach cash flow breakeven and profitability within a near-term planning horizon.
Shareholder Return Plan: Outset Medical is focused on aligning employee interests with those of shareholders through a proposed increase in the stock pool for employee grants and an increase in the employee stock purchase plan. These initiatives are aimed at attracting and retaining top talent as the company aims to reignite growth and build for the long term.
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
The earnings call shows strong financial performance with reduced losses and improved cash position. Conservative guidance is balanced by optimism in recurring revenue and pipeline strength. The Q&A section highlights strategic improvements in sales productivity and market expansion, particularly in enterprise and home hemodialysis channels. Concerns about cash burn in 2026 are noted but don't overshadow the overall positive outlook. Given the strategic initiatives and strong recurring revenue, the stock is likely to experience a positive movement in the short term.
The earnings call presents a positive outlook with revenue and recurring revenue growth, improved gross margins, and reduced operating expenses. The Q&A section reinforced confidence in sales transformation and balance sheet improvements. Despite conservative guidance, the company is on track for a strong 2025 with reduced cash usage and a focus on market expansion. The shareholder return plan is also a positive aspect. However, regulatory and supply chain risks are noted, but the overall sentiment is positive, predicting a 2% to 8% stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
